SOURCE: GlobeImmune, Inc.

GlobeImmune, Inc.

January 19, 2010 07:00 ET

GlobeImmune Announces $17.5 Million Series E Financing

LOUISVILLE, CO--(Marketwire - January 19, 2010) - GlobeImmune Inc., a company developing novel therapies for patients with cancer and infectious diseases, today announced a Series E Preferred Stock financing of $17.5 million. The round was led by new investors Generali Financial Holding and BSI SA. Advisory for the new investors was BSI Healthcapital SA of Lugano, Switzerland. Existing investors in GlobeImmune also participated in the financing.

BSI Healthcapital SA is the international investment advisory company for the healthcare industry of Generali Group (a major international firm in the insurance and financial market) and BSI SA (a Swiss bank founded in 1873, fully owned by Generali). BSI Healthcapital's focus is in privately-held biopharmaceutical companies with proprietary platform technology to discover new therapeutics in cancer, CNS, metabolic and infectious diseases.

"We are delighted to have Generali and BSI as new investors in GlobeImmune, and are appreciative of the continued support of our current investors," said Timothy C. Rodell, M.D., CEO of GlobeImmune. "This financing strengthens the Company's balance sheet as we continue to move our clinical programs forward."

"We are proud that BSI and Generali led this round, along with the participation of the prominent existing investors, and are very impressed by the therapeutic approach, product pipeline, and clinical data of GlobeImmune," said Davide Gai, CEO of BSI Healthcapital. "We look forward to working together with the fine management team."


GlobeImmune is a private biopharmaceutical company developing active immunotherapy products called Tarmogens® for the treatment of cancer and infectious diseases. The Company has three products in clinical development; the two most advanced products are in randomized, controlled, multi-center phase 2b clinical trials. The Company's lead infectious disease program, GI-5005, is a potential treatment for chronic hepatitis C (HCV) infection. GI-5005 is currently being developed in combination with the current standard of care, pegylated interferon and ribavirin. Treatment-naïve patients with genotype 1 HCV receiving GI-5005 and standard of care demonstrated a 15% absolute improvement in complete response rate at the end of 48 weeks of treatment relative to patients receiving standard of care alone. The Company's lead oncology program, GI-4000, targets cancers caused by a mutated Ras protein. GI-4000 is being evaluated as a treatment for pancreas cancer, non-small cell lung carcinoma and other solid tumors. GI-4000 is currently in a randomized, active control, adjuvant, phase 2b trial in resected pancreas cancer patients in combination with the current standard of care, gemcitabine. In May 2009, the Company announced a global partnership with Celgene focused on the discovery, development and commercialization of multiple product candidates for the treatment of cancer.

For additional information, please visit the Company's website at

This press release contains forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward-looking statements contained in this release. This release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any of the securities nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification of the securities under the securities laws of any such state.